Virbac SA/ADR
Virbac SA/ADR is a Healthcare company operating in Drug Manufacturers - General with a $3.42B market cap.
Most recent earnings call: Q2 FY25 on Sep 15, 2025.
3 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks VRBCF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VRBCF.
$ curl https://api.spokenalpha.com/v1/companies/VRBCFFAQ
Spoken Alpha indexes VRBCF's earnings call transcripts at https://spokenalpha.com/companies/VRBCF. Each call links to attributed speakers and parsed analyst Q&A.
Virbac SA/ADR (VRBCF) held its most recent earnings call on 2025-09-15, covering fiscal Q2 2025.
Virbac SA/ADR (VRBCF) operates in the Healthcare sector (Drug Manufacturers - General industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $1.65 | $1.34 | +23.1% | +1.6% | +0.5% |
| Q4 FY2025 | $1.86 | $1.35 | +37.7% | +4.9% | +6.7% |
| Q3 FY2025 | $1.76 | $1.29 | +36.6% | +5.1% | +8.0% |
| Q2 FY2025 | $1.72 | $1.27 | +35.2% | -2.5% | -0.3% |
| Q1 FY2024 | $1.71 | $1.36 | +25.6% | 0.0% | +2.4% |
| Q4 FY2024 | $1.76 | $1.31 | +34.5% | +4.6% | +3.1% |
| Q3 FY2024 | $1.84 | $1.43 | +28.8% | +4.0% | +2.0% |
| Q2 FY2024 | $1.94 | $1.41 | +37.4% | -2.5% | -1.2% |
| Q1 FY2023 | $1.86 | $1.45 | +28.4% | -2.6% | -1.8% |
| Q4 FY2023 | $1.96 | $1.54 | +27.3% | -4.6% | -4.9% |